Stabilized next-generation recombinant human acid alpha-glucosidase ATB200 clears accumulated glycogen and reverses cellular dysfunction to increase functional muscle strength in a mouse model of Pompe disease

2017 ◽  
Vol 120 (1-2) ◽  
pp. S42
Author(s):  
Hung Do ◽  
Yi Lun ◽  
Su Xu ◽  
Rebecca Soska ◽  
Anju Nair ◽  
...  
Keyword(s):  
Muscle Strength ◽  
Mouse Model ◽  
Pompe Disease ◽  
Next Generation ◽  
Human Acid ◽  
Cellular Dysfunction ◽  
Alpha Glucosidase

Pregnancy in a Case of Pompe Disease Treated with Recombinant Human Acid Alpha Glucosidase (Myozyme)

2011 ◽  
Vol 33 (6) ◽  
pp. S22
Author(s):  
F. Zagnoli ◽  
A. Leblanc ◽  
C. Blanchard ◽  
A. Philippe ◽  
M. Lastennet
Keyword(s):  
Pompe Disease ◽  
Human Acid ◽  
Alpha Glucosidase

Benefit of Recombinant Human Acid Alpha Glucosidase Treatment (Myozyme) in Late Onset Pompe Disease: About Five Cases Treated for 3 Years

2011 ◽  
Vol 33 (6) ◽  
pp. S23
Author(s):  
F. Zagnoli ◽  
A. Leblanc ◽  
C. Blanchard ◽  
A. Philippe ◽  
M. Lastennet
Keyword(s):  
Pompe Disease ◽  
Late Onset ◽  
Human Acid ◽  
Alpha Glucosidase

scholarly journals The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease

PLoS ONE ◽  
2012 ◽  
Vol 7 (7) ◽  
pp. e40776 ◽  
Author(s):  
Richie Khanna ◽  
John J. Flanagan ◽  
Jessie Feng ◽  
Rebecca Soska ◽  
Michelle Frascella ◽  
...  
Keyword(s):  
Mouse Model ◽  
Pompe Disease ◽  
Pharmacological Chaperone ◽  
Human Acid
Sign in / Sign up

Export Citation Format

Share Document